---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-265708"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:17:54.805032+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Seres Q3 net income $8.2M on VOWST gain; cash runway through Q2 2026; SER-155 Phase 2 protocol finalized pending funding

## Summary
- Net income from continuing ops $8.2M vs loss of $51.0M in Q3 2024, driven by $27.2M gain on VOWST sale.
- Cash and equivalents $47.6M; expects to fund operations only through Q2 2026, noting ongoing capital needs.
- FDA feedback received; SER-155 Phase 2 protocol for BSI prevention in allo-HSCT being finalized, pending study funding.
- CARB-X grant of up to $3.6M awarded for oral liquid formulation of SER-155; IST in irEC initial results expected early 2026.
- Cost-reduction measures implemented including workforce decrease; R&D expense $12.6M, G&A $9.5M in Q3.

## SEC filing metadata
- accession: 0001193125-25-265708
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312525265708/0001193125-25-265708-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312525265708/d27174d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-265708
- JSON: https://secwatch.observer/filing/0001193125-25-265708.json
- Plain text: https://secwatch.observer/filing/0001193125-25-265708.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.